Lupin appoints Martin Mercer as head of Latin American biz

Drug major Lupin Monday appointed Martin Mercer as President of its Latin American business with immediate effect.

Lupin, Boehringer Ingelheim to co-market linagliptin in India

Drug majors Lupin and Boehringer Ingelheim on Wednesday announced a strategic alliance to co-market anti-diabetes drug linagliptin in India.

India drugmaker stocks exception in Asian rout

In Mumbai trading so far this year, Lupin Ltd has climbed 32 percent, Dr. Reddy`s 31 percent, Glenmark Pharmaceuticals 42 percent and Wockhardt 29 percent.

'US nod to Lupin's anti-cholesterol drug may not fatten up firm financials'

Lupin Ltd's anti-cholesterol drug securing USFDA approval is a positive development but may not contribute to the company's financials in a major way.

Lupin gets shareholders nod to raise up to Rs 7,500 crore

Drug major Lupin on Saturday said it has received approval from its shareholders to raise up to Rs 7,500 crore through issue of securities.

Lupin Q1 net dips by 16% at Rs 525.02 cr

The company had posted a net profit after taxes and minority interest of Rs 624.74 crore for the corresponding period of the previous fiscal, Lupin said in a filing to BSE.

Brazil suspends import of Lupin's antibiotic ingredients

Brazilian drug regulator ANVISA has suspended import of active ingredients produced by pharma major Lupin used to make antibiotics, citing "unsatisfactory inputs" and deviation from good manufacturing practices (GMP).

Stocks markets head for 2-1/2-month closing high; HDFC Bank, Lupin lead

India`s stock markets rose on Friday to head towards their highest close in 2-1/2 months as HDFC Bank Ltd rose on relative valuations, while drugmaker Lupin Ltd rose after an acquisition in Russia.

Lupin up 2.5% on Russia's Biocom acquisition

Shares of drug major Lupin on Friday gained 2.5 percent after the company announced acquisition of Russia's Biocom, marking its foray into the Russian pharma market, which is expected to be one of the top eight in the world by 2018.

Lupin acquires Russian drug firm Biocom

The company has acquired 100 per cent equity stake in ZAO Biocom in Russia subject to certain closing conditions, Lupin Ltd said in a statement without disclosing the financial details.

Lupin to beef up branded portfolio through alliances

"In 2015-16, the company remains committed to continuing to strengthen its branded portfolio with the launch of additional products by not only creating alliances but also developing its own pipeline and making strategic brand acquisitions in US markets," Lupin said in its annual report here.

Lupin gets Board's nod to raise funds up to Rs 7,500 crore
Lupin gets Board's nod to raise funds up to Rs 7,500 crore

Drug major Lupin on Tuesday said its Board of Directors have given in-principle approval for raising funds of up to Rs 7,500 crore.

Lupin shares gain on inclusion in Sensex
Lupin shares gain on inclusion in Sensex

Shares of drugmaker Lupin rose by almost 2 percent after the stock became part of the BSE benchmark Sensex from on Monday.

Lupin to replace Tata Power on Sensex from Monday

Besides, a host of changes would also be effective in various other indices, where Adani Power would be dropped from the BSE 100 index.

Lupin submits fresh studies for two products suspended by EMA

The Mumbai-based firm along with many other companies had received communication from EMA for suspension of Trimetazidine MR 35 mg and Cefpodoxime 200 mg tablets in January 2015.

BSE drops Tata Power from Sensex; Lupin to come in

Private sector electricity producer Tata Power will move out of the stock market benchmark index Sensex and will be replaced by drugmaker Lupin.

Lupin acquires Brazilian drug firm Medquimica

Drug major Lupin Wednesday announced acquisition of Brazil's Medquimica Industria Farmaceutica SA, marking its foray into the Latin American nation.

Lupin launches anti-bacterial Zaxine tablets in Canada

Zaxine 550 mg (rifaximin) is a long-term antibiotic treatment drug for adults living with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis).

Lupin to acquire additional 40% stake in SA's Pharma Dynamics

Lupin had earlier acquired 60 per cent stake in the South African (SA) firm in September, 2008.

Lupin gets USFDA nod for ophthalmic solution

The company said it has received the final approval for its product, a generic version of Allergan Inc's Lumigan Ophthalmic Solution, from the US Food and Drug Administration (USFDA).